New Biomarkers and Treatment Advances in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is a specific subtype of breast cancer lacking hormone receptor expression and HER2 gene amplification. TNBC represents a heterogeneous subtype of breast cancer, characterized by poor prognosis, high invasiveness, high metastatic potential, and a tendency to relapse. In this review, the specific molecular subtypes and pathological aspects of triple-negative breast cancer are illustrated, with particular attention to the biomarker characteristics of TNBC, namely: regulators of cell proliferation and migration and angiogenesis, apoptosis-regulating proteins, regulators of DNA damage response, immune checkpoints, and epigenetic modifications. This paper also focuses on omics approaches to exploring TNBC, such as genomics to identify cancer-specific mutations, epigenomics to identify altered epigenetic landscapes in cancer cells, and transcriptomics to explore differential mRNA and protein expression. Moreover, updated neoadjuvant treatments for TNBC are also mentioned, underlining the role of immunotherapy and novel and targeted agents in the treatment of TNBC.

[1]  M. Akhtar,et al.  Myricetin-induced apoptosis in triple-negative breast cancer cells through inhibition of the PI3K/Akt/mTOR pathway , 2022, Medical Oncology.

[2]  L. Cerchia,et al.  Aptamer-Functionalized Nanoparticles Mediate PD-L1 siRNA Delivery for Effective Gene Silencing in Triple-Negative Breast Cancer Cells , 2022, Pharmaceutics.

[3]  Xiaomei Zhou,et al.  Current landscape of personalized clinical treatments for triple-negative breast cancer , 2022, Frontiers in Pharmacology.

[4]  T. Nielsen,et al.  Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications , 2022, Journal of Experimental & Clinical Cancer Research.

[5]  G. Sala,et al.  Breast cancer in the era of integrating “Omics” approaches , 2022, Oncogenesis.

[6]  A. Batra,et al.  Moment of truth-adding carboplatin to neoadjuvant/adjuvant chemotherapy in triple negative breast cancer improves overall survival: An individual participant data and trial-level Meta-analysis , 2022, Breast.

[7]  Min Hwan Kim,et al.  Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. , 2022, The New England journal of medicine.

[8]  Yuan Li,et al.  Recent advances of transcriptomics and proteomics in triple‐negative breast cancer prognosis assessment , 2022, Journal of cellular and molecular medicine.

[9]  C. Francavilla,et al.  Fibroblast growth factor receptor signalling dysregulation and targeting in breast cancer , 2022, Open Biology.

[10]  Fan Yang,et al.  Comprehensive metabolomics expands precision medicine for triple-negative breast cancer , 2022, Cell Research.

[11]  H. Yao,et al.  LncRNA Uc003xsl.1-Mediated Activation of the NFκB/IL8 Axis Promotes Progression of Triple-Negative Breast Cancer , 2021, Cancer research.

[12]  L. Gianni,et al.  Treatment landscape of triple-negative breast cancer — expanded options, evolving needs , 2021, Nature Reviews Clinical Oncology.

[13]  D. Ajarim,et al.  Weekly Paclitaxel given concurrently with Durvalumab has a favorable safety profile in triple-negative metastatic breast cancer , 2021, Scientific Reports.

[14]  D. Singh,et al.  TNBC: Potential Targeting of Multiple Receptors for a Therapeutic Breakthrough, Nanomedicine, and Immunotherapy , 2021, Biomedicines.

[15]  Carlos L. Arteaga,et al.  FGFR signaling and endocrine resistance in breast cancer: Challenges for the clinical development of FGFR inhibitors. , 2021, Biochimica et biophysica acta. Reviews on cancer.

[16]  J. S. Kim,et al.  Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer , 2021, Breast Cancer Research and Treatment.

[17]  Jeonghee Cho,et al.  Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer , 2021, Pharmaceuticals.

[18]  T. Mikami,et al.  Carcinogenesis of Triple-Negative Breast Cancer and Sex Steroid Hormones , 2021, Cancers.

[19]  Z. Kolár̂,et al.  Molecular Prognostic and Predictive Markers in Triple - Negative Breast Cancer , 2021, Breast Cancer [Working Title].

[20]  R. Bindra,et al.  The Role of Mismatch Repair in Glioblastoma Multiforme Treatment Response and Resistance. , 2021, Neurosurgery clinics of North America.

[21]  Chao Dong,et al.  Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer , 2021, Frontiers in Pharmacology.

[22]  Q. Sun,et al.  Mismatch Repair Deficiency and Microsatellite Instability in Triple-Negative Breast Cancer: A Retrospective Study of 440 Patients , 2021, Frontiers in Oncology.

[23]  Jeonghee Cho,et al.  Dual Inhibition of AKT and MEK Pathways Potentiates the Anti-Cancer Effect of Gefitinib in Triple-Negative Breast Cancer Cells , 2021, Cancers.

[24]  V. Tzelepi,et al.  Epigenetic Alterations in Triple-Negative Breast Cancer—The Critical Role of Extracellular Matrix , 2021, Cancers.

[25]  N. Lahmidani,et al.  Microsatellite Instability Analysis in Gastric Carcinomas of Moroccan Patients. , 2021, Genetic testing and molecular biomarkers.

[26]  V. Balakrishnan,et al.  Triple Negative Breast Cancer: A Review of Present and Future Diagnostic Modalities , 2021, Medicina.

[27]  Jin-hai Tang,et al.  The long non‐coding RNA landscape in triple‐negative breast cancer , 2020, Cell proliferation.

[28]  M. Esteller,et al.  Triple Negative Breast Cancer in the Era of miRNA. , 2020, Critical reviews in oncology/hematology.

[29]  M. Lustberg,et al.  Triple-negative breast cancer: promising prognostic biomarkers currently in development , 2020, Expert review of anticancer therapy.

[30]  L. Hou,et al.  Effects of miR-93 on epithelial-to-mesenchymal transition and vasculogenic mimicry in triple-negative breast cancer cells , 2020, Molecular medicine reports.

[31]  Kyudong Han,et al.  Molecular subtypes of triple-negative breast cancer: understanding of subtype categories and clinical implication , 2020, Genes & Genomics.

[32]  Athirah Bakhtiar,et al.  Bioengineered siRNA-Based Nanoplatforms Targeting Molecular Signaling Pathways for the Treatment of Triple Negative Breast Cancer: Preclinical and Clinical Advancements , 2020, Pharmaceutics.

[33]  I. Voutsadakis.  8p11.23 Amplification in Breast Cancer: Molecular Characteristics, Prognosis and Targeted Therapy , 2020, Journal of clinical medicine.

[34]  H. Iwata,et al.  Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial , 2020, The Lancet.

[35]  J. Kopczyński,et al.  Hormonal Receptor Status Determines Prognostic Significance of FGFR2 in Invasive Breast Carcinoma , 2020, Cancers.

[36]  S. Dunn,et al.  The dawn of targeted therapies for triple negative breast cancer (TNBC): a snapshot of investigational drugs in phase I and II trials , 2020, Expert opinion on investigational drugs.

[37]  Xian-feng Ding,et al.  Roles of miRNA and IncRNA in triple-negative breast cancer , 2020, Journal of Zhejiang University-SCIENCE B.

[38]  B. Baradaran,et al.  Prognostic Role and Clinical Significance of Tumor-Infiltrating Lymphocyte (TIL) and Programmed Death Ligand 1 (PD-L1) Expression in Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis Study , 2020, Diagnostics.

[39]  M. Duffy,et al.  Targeting p53 for the treatment of cancer. , 2020, Seminars in cancer biology.

[40]  L. Pusztai,et al.  PD-L1 Protein Expression on Both Tumor Cells and Macrophages are Associated with Response to Neoadjuvant Durvalumab with Chemotherapy in Triple-negative Breast Cancer , 2020, Clinical Cancer Research.

[41]  S. Oesterreich,et al.  FGFR4: A promising therapeutic target for breast cancer and other solid tumors. , 2020, Pharmacology & therapeutics.

[42]  Keng Wong Kah.  DNMT1: A Key Drug Target in Triple-Negative Breast Cancer. , 2020, Seminars in cancer biology.

[43]  Longlong Wang,et al.  Herb-sourced emodin inhibits angiogenesis of breast cancer by targeting VEGFA transcription , 2020, Theranostics.

[44]  P. Conte,et al.  Novel Nuclear Medicine Imaging Applications in Immuno-Oncology , 2020, Cancers.

[45]  H. Yao,et al.  Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial , 2020, Journal for immunotherapy of cancer.

[46]  L. Farahmand,et al.  Breast cancer: Biology, biomarkers, and treatments. , 2020, International immunopharmacology.

[47]  Zihai Li,et al.  Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy , 2020, Journal of Hematology & Oncology.

[48]  Hailin Tang,et al.  Long non-coding RNA HUMT hypomethylation promotes lymphangiogenesis and metastasis via activating FOXK1 transcription in triple-negative breast cancer , 2020, Journal of Hematology & Oncology.

[49]  Mengquan Li,et al.  lncRNA GAS5‐promoted apoptosis in triple‐negative breast cancer by targeting miR‐378a‐5p/SUFU signaling , 2020, Journal of cellular biochemistry.

[50]  A. Flaus,et al.  Survival outcomes are associated with genomic instability in luminal breast cancers. , 2020, PloS one.

[51]  G. Tortora,et al.  Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors , 2020, Expert opinion on pharmacotherapy.

[52]  Zijing Hu,et al.  FGF/FGFR signaling pathway involved resistance in various cancer types , 2020, Journal of Cancer.

[53]  A. Córdoba,et al.  ADAM12 is A Potential Therapeutic Target Regulated by Hypomethylation in Triple-Negative Breast Cancer , 2020, International journal of molecular sciences.

[54]  R. Daly,et al.  FGFR3 signaling and function in triple negative breast cancer , 2020, Cell Communication and Signaling.

[55]  Deepak K. Singh,et al.  LncRNA-mediated regulation of SOX9 expression in basal subtype breast cancer cells , 2019, RNA.

[56]  Liewei Wang,et al.  Targeting DNA methylation for treating triple-negative breast cancer , 2019, Pharmacogenomics.

[57]  Ming Xu,et al.  Gene and lncRNA co-expression network analysis reveals novel ceRNA network for triple-negative breast cancer , 2019, Scientific Reports.

[58]  Bowen Zhang,et al.  Long non-coding RNA DRHC inhibits the proliferation of cancer cells in triple negative breast cancer by downregulating long non-coding RNA HOTAIR. , 2019, Oncology letters.

[59]  G. Giaccone,et al.  IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC , 2019, Annals of Oncology.

[60]  Chao Zhang,et al.  Characterization of ceRNA network to reveal potential prognostic biomarkers in triple-negative breast cancer , 2019, PeerJ.

[61]  Wei Zhang,et al.  LncRNA AWPPH and miRNA‐21 regulates cancer cell proliferation and chemosensitivity in triple‐negative breast cancer by interacting with each other , 2019, Journal of cellular biochemistry.

[62]  Bo Zhou,et al.  LncRNA HEIH regulates cell proliferation and apoptosis through miR-4458/SOCS1 axis in triple-negative breast cancer , 2019, Human Cell.

[63]  J. Tu,et al.  microRNA-21 promotes breast cancer proliferation and metastasis by targeting LZTFL1 , 2019, BMC Cancer.

[64]  Jianshi Du,et al.  MicroRNA-206 inhibits metastasis of triple-negative breast cancer by targeting transmembrane 4 L6 family member 1 , 2019, Cancer management and research.

[65]  Jian Yin,et al.  CCAT1 promotes triple-negative breast cancer progression by suppressing miR-218/ZFX signaling , 2019, Aging.

[66]  Itay Tirosh,et al.  Single-Cell RNA Sequencing in Cancer: Lessons Learned and Emerging Challenges. , 2019, Molecular cell.

[67]  T. Xiang,et al.  RETRACTED ARTICLE: Up-regulated lncRNA GAS5 promotes chemosensitivity and apoptosis of triple-negative breast cancer cells , 2019, Cell cycle.

[68]  N. Turner,et al.  Targeting the PI3-kinase pathway in triple negative breast cancer. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[69]  Z. Stadler,et al.  Immunotherapy in colorectal cancer: rationale, challenges and potential , 2019, Nature Reviews Gastroenterology & Hepatology.

[70]  Qin Li,et al.  Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy , 2019, Journal of Hematology & Oncology.

[71]  J. Aster,et al.  AL101 mediated tumor inhibition in notch-altered TNBC PDX models. , 2019, Journal of Clinical Oncology.

[72]  H. Rugo,et al.  Alpelisib for PIK3CA‐Mutated, Hormone Receptor–Positive Advanced Breast Cancer , 2019, The New England journal of medicine.

[73]  G. Tse,et al.  Molecular Classification of Breast Cancer. , 2019, Advances in anatomic pathology.

[74]  Ning Zhang,et al.  Epigenetic regulation of NAMPT by NAMPT-AS drives metastatic progression in triple-negative breast cancer. , 2019, Cancer research.

[75]  Q. Zhan,et al.  Transcriptional Downregulation of miR-4306 serves as a New Therapeutic Target for Triple Negative Breast Cancer , 2019, Theranostics.

[76]  S. Kuemmel,et al.  Abstract PD5-01: KEYNOTE-173: Phase 1b multicohort study of pembrolizumab (Pembro) in combination with chemotherapy as neoadjuvant treatment for triple-negative breast cancer (TNBC) , 2019, Poster Discussion Abstracts.

[77]  K. Polyak,et al.  Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. , 2019, Cancer discovery.

[78]  Wei Li,et al.  OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[79]  Yujing Li,et al.  Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer , 2019, Nature Nanotechnology.

[80]  G. Gibson.  Going to the negative: genomics for optimized medical prescription , 2018, Nature Reviews Genetics.

[81]  G. Freeman,et al.  Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer , 2018, British Journal of Cancer.

[82]  R. Trojanec,et al.  Genetic Markers in Triple‐Negative Breast Cancer , 2018, Clinical breast cancer.

[83]  D. Jankovic,et al.  Early diagnosis and detection of breast cancer. , 2018, Technology and health care : official journal of the European Society for Engineering and Medicine.

[84]  Dong-Wan Kim,et al.  Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma , 2018, Oncoimmunology.

[85]  M. Scorsetti,et al.  Checkpoint inhibitors as treatment for malignant gliomas: "A long way to the top". , 2018, Cancer treatment reviews.

[86]  Barbara Pasculli,et al.  Epigenetics of breast cancer: Biology and clinical implication in the era of precision medicine. , 2018, Seminars in cancer biology.

[87]  Jun Zhou,et al.  Long noncoding RNA GAS5 suppresses triple negative breast cancer progression through inhibition of proliferation and invasion by competitively binding miR-196a-5p. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[88]  A. Munshi,et al.  Role of p53 Gene in Breast Cancer: Focus on Mutation Spectrum and Therapeutic Strategies. , 2018, Current pharmaceutical design.

[89]  Yu-jie Ma,et al.  LncRNA MIR100HG promotes cell proliferation in triple-negative breast cancer through triplex formation with p27 loci , 2018, Cell Death & Disease.

[90]  X. Guan,et al.  Therapeutic landscape in mutational triple negative breast cancer , 2018, Molecular Cancer.

[91]  M. Ceppi,et al.  Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[92]  Chengzhong Ye,et al.  Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis , 2018, Nature Medicine.

[93]  R. Kordek,et al.  MicroRNAs in regulation of triple-negative breast cancer progression , 2018, Journal of Cancer Research and Clinical Oncology.

[94]  J. Issa,et al.  TET1-Mediated Hypomethylation Activates Oncogenic Signaling in Triple-Negative Breast Cancer. , 2018, Cancer research.

[95]  J. Bergh,et al.  KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant therapy followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC). , 2018 .

[96]  B. Tunca,et al.  Triple negative breast cancer: new therapeutic approaches and BRCA status , 2018, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[97]  Paul Ellis,et al.  Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial , 2018, Nature Medicine.

[98]  Hui Zhou,et al.  Applications of RNA Indexes for Precision Oncology in Breast Cancer , 2018, Genom. Proteom. Bioinform..

[99]  W. Symmans,et al.  Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. , 2018, The Lancet. Oncology.

[100]  M. Duffy,et al.  Mutant p53 in breast cancer: potential as a therapeutic target and biomarker , 2018, Breast Cancer Research and Treatment.

[101]  J. Cortés,et al.  Targeting FGFR pathway in breast cancer. , 2018, Breast.

[102]  Lavanya Ponnusamy,et al.  Epigenetic regulation of miR-200 as the potential strategy for the therapy against triple-negative breast cancer. , 2018, Gene.

[103]  Naijun Yuan,et al.  Integrative analysis of lncRNAs and miRNAs with coding RNAs associated with ceRNA crosstalk network in triple negative breast cancer , 2017, OncoTargets and therapy.

[104]  J. Guan,et al.  Breast Cancer: Multiple Subtypes within a Tumor? , 2017, Trends in cancer.

[105]  Yul Ri Chung,et al.  Prognostic value of microRNA-9 and microRNA-155 expression in triple-negative breast cancer. , 2017, Human pathology.

[106]  M. Espié,et al.  Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. , 2017, The Lancet. Oncology.

[107]  Ludmila V. Danilova,et al.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.

[108]  Hongming Song,et al.  The microRNAs miR-200b-3p and miR-429-5p target the LIMK1/CFL1 pathway to inhibit growth and motility of breast cancer cells. , 2017, Oncotarget.

[109]  J. Liu,et al.  miR-200b inhibits proliferation and metastasis of breast cancer by targeting fucosyltransferase IV and α1,3-fucosylated glycans , 2017, Oncogenesis.

[110]  Jian-jun Li,et al.  MicroRNA-211-5p suppresses tumour cell proliferation, invasion, migration and metastasis in triple-negative breast cancer by directly targeting SETBP1 , 2017, British Journal of Cancer.

[111]  A. Giordano,et al.  Suppressive role exerted by microRNA-29b-1-5p in triple negative breast cancer through SPIN1 regulation , 2017, Oncotarget.

[112]  W. Baze,et al.  Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA) , 2017, Molecular Cancer Therapeutics.

[113]  G. Hortobagyi,et al.  PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression , 2017, Clinical Cancer Research.

[114]  Y. Bignon,et al.  miR-10b, miR-26a, miR-146a And miR-153 Expression in Triple Negative Vs Non Triple Negative Breast Cancer: Potential Biomarkers , 2017, Pathology & Oncology Research.

[115]  J. Yu,et al.  MicroRNA-182 targets FOXF2 to promote the development of triple-negative breast cancer. , 2016, Neoplasma.

[116]  G. Calin,et al.  MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase , 2016, Oncotarget.

[117]  Ava Kwong,et al.  miR-199a-5p confers tumor-suppressive role in triple-negative breast cancer , 2016, BMC Cancer.

[118]  Y. Pommier,et al.  Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action , 2016, Science Translational Medicine.

[119]  Philippe Foubert,et al.  PI3Kγ is a molecular switch that controls immune suppression , 2016, Nature.

[120]  Hirohito Yamaguchi,et al.  A perspective on anti-EGFR therapies targeting triple-negative breast cancer. , 2016, American journal of cancer research.

[121]  Bing-he Xu,et al.  Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial , 2016, Oncotarget.

[122]  J. Bartlett,et al.  EMT in Breast Carcinoma—A Review , 2016, Journal of clinical medicine.

[123]  Feng Yan,et al.  MicroRNA-145 functions as a tumor suppressor by targeting matrix metalloproteinase 11 and Rab GTPase family 27a in triple-negative breast cancer , 2016, Cancer Gene Therapy.

[124]  A. Shilatifard,et al.  Epigenetic balance of gene expression by Polycomb and COMPASS families , 2016, Science.

[125]  Brian J. Bennett,et al.  Nutrigenomics, the Microbiome, and Gene-Environment Interactions: New Directions in Cardiovascular Disease Research, Prevention, and Treatment A Scientific Statement From the American Heart Association , 2016, Circulation. Cardiovascular genetics.

[126]  Hongwei Liang,et al.  Slug-upregulated miR-221 promotes breast cancer progression through suppressing E-cadherin expression , 2016, Scientific Reports.

[127]  F. Penault-Llorca,et al.  Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer , 2016, International journal of cancer.

[128]  Lin Zhang,et al.  Long noncoding RNA LINP1 regulates double strand DNA break repair in triple negative breast cancer , 2016, Nature Structural &Molecular Biology.

[129]  R. Ortíz-López,et al.  Triple negative breast cancer: Deciphering the biology and heterogeneity , 2016 .

[130]  B. Ozpolat,et al.  FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells , 2016, Oncotarget.

[131]  J. Taube,et al.  Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer. , 2016, Cancer research.

[132]  E. Giovannetti,et al.  MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients , 2015, Oncotarget.

[133]  Razelle Kurzrock,et al.  The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing , 2015, Clinical Cancer Research.

[134]  Jun Wang,et al.  miR-200a inhibits migration of triple-negative breast cancer cells through direct repression of the EPHA2 oncogene. , 2015, Carcinogenesis.

[135]  F. Sinicrope,et al.  Microsatellite Instability Testing and Its Role in the Management of Colorectal Cancer , 2015, Current Treatment Options in Oncology.

[136]  Jenny G. Parvani,et al.  Silencing β3 Integrin by Targeted ECO/siRNA Nanoparticles Inhibits EMT and Metastasis of Triple-Negative Breast Cancer. , 2015, Cancer research.

[137]  Z. Jehan,et al.  Loss of PTEN expression is associated with aggressive behavior and poor prognosis in Middle Eastern triple-negative breast cancer , 2015, Breast Cancer Research and Treatment.

[138]  L. Emens,et al.  The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies , 2015, Cancer Immunology Research.

[139]  Guanming Wu,et al.  Manic fringe promotes a claudin-low breast cancer phenotype through notch-mediated PIK3CG induction. , 2015, Cancer research.

[140]  Kenneth P. Nephew,et al.  Dual regulation by microRNA-200b-3p and microRNA-200b-5p in the inhibition of epithelial-to-mesenchymal transition in triple-negative breast cancer , 2015, Oncotarget.

[141]  R. Vyzula,et al.  Ixabepilone alone or with cetuximab as first-line treatment for advanced/metastatic triple-negative breast cancer. , 2015, Clinical breast cancer.

[142]  K. Tomczak,et al.  The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge , 2015, Contemporary oncology.

[143]  P. Rejto,et al.  PEST Domain Mutations in Notch Receptors Comprise an Oncogenic Driver Segment in Triple-Negative Breast Cancer Sensitive to a γ-Secretase Inhibitor , 2015, Clinical Cancer Research.

[144]  F. Bertucci,et al.  Prognostic and predictive value of PDL1 expression in breast cancer , 2014, Oncotarget.

[145]  J. Bergh,et al.  miR‐206 inhibits cell migration through direct targeting of the actin‐binding protein Coronin 1C in triple‐negative breast cancer , 2014, Molecular oncology.

[146]  P. Neven,et al.  Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[147]  G. Hostetter,et al.  Stromal expression of miR-21 identifies high-risk group in triple-negative breast cancer. , 2014, The American journal of pathology.

[148]  Gideon Blumenthal,et al.  Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis , 2014, The Lancet.

[149]  M. Rezai,et al.  Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. , 2014, The Lancet. Oncology.

[150]  M. Rezai,et al.  Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): Results from GeparSixto. , 2014 .

[151]  Gwyn T. Williams,et al.  Regulation of apoptosis by long non-coding RNA GAS5 in breast cancer cells: implications for chemotherapy , 2014, Breast Cancer Research and Treatment.

[152]  Rim S Ishak,et al.  Cutaneous manifestations of anti-angiogenic therapy in oncology: Review with focus on VEGF inhibitors. , 2014, Critical reviews in oncology/hematology.

[153]  Sean Ferree,et al.  Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens , 2014, BMC Cancer.

[154]  R. Laing,et al.  Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial. , 2014, The Lancet. Oncology.

[155]  Sun Yan,et al.  Critical role of miR-10b in transforming growth factor-β1-induced epithelial–mesenchymal transition in breast cancer , 2014, Cancer Gene Therapy.

[156]  P. Sharma,et al.  PD-L1 Expression in Triple-Negative Breast Cancer , 2014, Cancer Immunology Research.

[157]  J. Pietenpol,et al.  Identification and use of biomarkers in treatment strategies for triple‐negative breast cancer subtypes , 2014, The Journal of pathology.

[158]  Rodney Rothstein,et al.  Repair of strand breaks by homologous recombination. , 2013, Cold Spring Harbor perspectives in biology.

[159]  G. Ball,et al.  Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[160]  N. McGranahan,et al.  The causes and consequences of genetic heterogeneity in cancer evolution , 2013, Nature.

[161]  V. Brouste,et al.  Comprehensive analysis of PTEN status in breast carcinomas , 2013, International journal of cancer.

[162]  L. Miele,et al.  Correlation of Notch1, pAKT and nuclear NF-κB expression in triple negative breast cancer. , 2013, American journal of cancer research.

[163]  Yan Wang,et al.  Expression and regulatory function of miRNA-182 in triple-negative breast cancer cells through its targeting of profilin 1 , 2013, Tumor Biology.

[164]  K. Gajiwala,et al.  Specific inhibition of Notch1 signaling enhances the antitumor efficacy of chemotherapy in triple negative breast cancer through reduction of cancer stem cells. , 2013, Cancer letters.

[165]  R. Gelber,et al.  Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX , 2012, Breast Cancer Research.

[166]  Jun Liang,et al.  Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors. , 2012, Journal of medicinal chemistry.

[167]  U. Rannug,et al.  High incidence of microsatellite instability and loss of heterozygosity in three loci in breast cancer patients receiving chemotherapy: a prospective study , 2012, BMC Cancer.

[168]  G. von Minckwitz,et al.  Neoadjuvant treatments for triple-negative breast cancer (TNBC). , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[169]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[170]  C. Perou,et al.  Lunatic fringe deficiency cooperates with the Met/Caveolin gene amplicon to induce basal-like breast cancer. , 2012, Cancer cell.

[171]  Irmtraud M. Meyer,et al.  The clonal and mutational evolution spectrum of primary triple-negative breast cancers , 2012, Nature.

[172]  F. Rodeghiero,et al.  Side effects of anti-angiogenic drugs. , 2012, Thrombosis research.

[173]  Sanjeev Misra,et al.  Comparative evaluation of the modified Scarff-Bloom-Richardson grading system on breast carcinoma aspirates and histopathology , 2012, CytoJournal.

[174]  Carlos Caldas,et al.  A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER‐positive breast cancer , 2012, The Journal of pathology.

[175]  S. Loibl,et al.  Lessons from the neoadjuvant setting on how best to choose adjuvant therapies. , 2011, Breast.

[176]  Z. Lou,et al.  Phosphorylation and Stabilization of Topoisomerase IIα Protein by p38γ Mitogen-activated Protein Kinase Sensitize Breast Cancer Cells to Its Poisons* , 2011, The Journal of Biological Chemistry.

[177]  R. Plummer.  Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer? , 2011, Breast Cancer Research.

[178]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[179]  J. Lubiński,et al.  Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[180]  G. Tang,et al.  The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[181]  M. Kurosumi,et al.  Pathological tumor response to neoadjuvant chemotherapy using anthracycline and taxanes in patients with triple-negative breast cancer. , 2011, Experimental and therapeutic medicine.

[182]  W. Jung,et al.  The Expression of ERCC1, RRM1, and BRCA1 in Breast Cancer According to the Immunohistochemical Phenotypes , 2011, Journal of Korean medical science.

[183]  R. Chacón,et al.  REVIEW Triple-negative , 2022 .

[184]  G. Viale,et al.  Management of triple negative breast cancer. , 2010, Breast.

[185]  C. Denkert,et al.  Effect of neoadjuvant anthracycline–taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study , 2010, Breast Cancer Research and Treatment.

[186]  H. Gómez,et al.  Breast cancer classification according to immunohistochemistry markers: subtypes and association with clinicopathologic variables in a peruvian hospital database. , 2010, Clinical breast cancer.

[187]  J. Dering,et al.  Cyclin D1 is a direct target of JAG1-mediated Notch signaling in breast cancer , 2010, Breast Cancer Research and Treatment.

[188]  Jorge S. Reis-Filho,et al.  Histological types of breast cancer: How special are they? , 2010, Molecular oncology.

[189]  P. Fasching,et al.  Impact of treatment characteristics on response of different breast cancer subtypes: Pooled multilayer analysis of the German neoadjuvant chemotherapy trials. , 2010 .

[190]  Cole Trapnell,et al.  Role of Rodent Secondary Motor Cortex in Value-based Action Selection Nih Public Access Author Manuscript , 2006 .

[191]  Z. Szallasi,et al.  Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[192]  M. Antoine,et al.  De la cellule mammaire normale à la cellule cancéreuse , 2010 .

[193]  S. Lowe,et al.  Tumor suppressive functions of p53. , 2009, Cold Spring Harbor perspectives in biology.

[194]  P. Fasching,et al.  Integrated meta-analysis on 6402 patients with early breast cancer receiving neoadjuvant anthracycline-taxane +/- trastuzumab containing chemotherapy. , 2009 .

[195]  Debra L Winkeljohn.  Triple-negative breast cancer. , 2008, Clinical journal of oncology nursing.

[196]  Alice T. Loo,et al.  PTEN-deficient cancers depend on PIK3CB , 2008, Proceedings of the National Academy of Sciences.

[197]  R. Mehta.  Dose-dense and/or metronomic schedules of specific chemotherapies consolidate the chemosensitivity of triple-negative breast cancer: a step toward reversing triple-negative paradox. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[198]  M. Loda,et al.  Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesis , 2008, Nature.

[199]  K. Hess,et al.  Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[200]  Fengqin Gao,et al.  Bcl2 negatively regulates DNA double-strand-break repair through a nonhomologous end-joining pathway. , 2008, Molecular cell.

[201]  S. Paik,et al.  Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[202]  N. Pimpinelli,et al.  A Key Role for Poly(ADP-Ribose) Polymerase-1 Activity during Human Dendritic Cell Maturation1 , 2007, The Journal of Immunology.

[203]  T. Waldman,et al.  Activated PI3K Signaling as an Endogenous Inducer of p53 in Human Cancer , 2007, Cell cycle.

[204]  Ajay N. Jain,et al.  Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. , 2006, Cancer cell.

[205]  Y. Pommier.  Topoisomerase I inhibitors: camptothecins and beyond , 2006, Nature Reviews Cancer.

[206]  J. Russo,et al.  Molecular basis of pregnancy-induced breast cancer protection , 2006, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[207]  S. Hussain,et al.  p53 biological network: at the crossroads of the cellular-stress response pathway and molecular carcinogenesis. , 2006, Journal of Nippon Medical School = Nippon Ika Daigaku zasshi.

[208]  G. Lockwood,et al.  High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. , 2005, Cancer research.

[209]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[210]  S. Artavanis-Tsakonas,et al.  Modulation of notch signaling elicits signature tumors and inhibits hras1-induced oncogenesis in the mouse mammary epithelium. , 2004, The American journal of pathology.

[211]  A. Hartmann,et al.  Microsatellite Instability Predicts Poor Short-Term Survival in Patients with Advanced Breast Cancer after High-Dose Chemotherapy and Autologous Stem-Cell Transplantation , 2004, Clinical Cancer Research.

[212]  Kang Tai,et al.  EARLY DETECTION AND VISUALIZATION OF BREAST TUMOR WITH THERMOGRAM AND NEURAL NETWORK , 2002 .

[213]  Ashok R Venkitaraman,et al.  Cancer Susceptibility and the Functions of BRCA1 and BRCA2 , 2002, Cell.

[214]  V. Rantanen,et al.  Additive and supra-additive cytotoxicity of cisplatin-taxane combinations in ovarian carcinoma cell lines , 1999, British Journal of Cancer.

[215]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[216]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[217]  Guohui Wang,et al.  Topoisomerase Inhibitors in Breast Cancer , 2019 .

[218]  Hailin Tang,et al.  Linc00152 promotes tumorigenesis by regulating DNMTs in triple-negative breast cancer. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[219]  C. Melincovici,et al.  Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis. , 2018, Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie.

[220]  H. Fang,et al.  miRNA-21 promotes proliferation and invasion of triple-negative breast cancer cells through targeting PTEN. , 2017, American journal of translational research.

[221]  C. Criscitiello,et al.  Targeting FGFR Pathway in Breast Cancer , 2017 .

[222]  D. Berry,et al.  Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[223]  Chun Zhou,et al.  Identification of microRNA-93 as a functional dysregulated miRNA in triple-negative breast cancer , 2014, Tumor Biology.

[224]  C. Osipo,et al.  The functional role of Notch signaling in triple-negative breast cancer. , 2013, Vitamins and hormones.

[225]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[226]  Giulia Bianchi,et al.  Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. , 2012, The Lancet. Oncology.

[227]  W. Coleman,et al.  Enhancement of chemotherapeutic efficacy in hypermethylator breast cancer cells through targeted and pharmacologic inhibition of DNMT3b , 2011, Breast Cancer Research and Treatment.

[228]  R. Weichselbaum,et al.  Predictors of competing mortality in advanced head and neck cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.